Try our beta test site
50 studies found for:    Open Studies | "Adenoviridae Infections"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Adenoviridae Infections"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Available Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Condition: Adenovirus
Intervention: Drug: Brincidofovir
2 Not yet recruiting Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A)
Condition: Adenovirus Infection
Intervention: Biological: Viralym-A
3 Recruiting A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis
Conditions: Keratoconjunctivitis Due to Adenovirus;   Viral Shedding
Interventions: Drug: Zirgan;   Drug: genteal gel
4 Recruiting Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against Epstein Barr Virus, Adenovirus, And Cytomegalovirus
Conditions: Epstein-Barr Virus Infections;   Adenovirus;   Cytomegalovirus Infections
Intervention: Biological: Cytotoxic T Lymphocytes
5 Not yet recruiting Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine Administered by Aerosol
Condition: Tuberculosis
Intervention: Biological: Ad5Ag85A
6 Recruiting Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation
Conditions: Cytomegalovirus Infection;   Adenovirus Infection
Intervention: Biological: virus-specific T-Cells
7 Recruiting Clinical Trial of Recombinant Adenovirus Type 5 AIDS Vaccine
Condition: Acquired Immunodeficiency Syndrome
Interventions: Biological: Ad5-gag;   Biological: Placebo
8 Recruiting Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer
Condition: Non-small Cell Lung Cancer Stage I
Intervention: Biological: Ad5-yCD/mutTKSR39rep-ADP Adenovirus
9 Recruiting Cytotoxic T Cells to Prevent Virus Infections
Conditions: CMV;   EBV;   Adenovirus Infections
Intervention: Drug: Cytotoxic T lymphocytes (CTLs).
10 Recruiting ARMS - Rapidly Generated Multivirus-Specific CTLs for the Prophylaxis And Treatment of EBV, CMV, Adenovirus, HHV6, and BK Virus
Condition: Viral Infection
Intervention: Biological: Multi-virus-specific cytotoxic T lymphocytes
11 Recruiting Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
Conditions: Brain Cancer;   Brain Neoplasm;   Glioma;   Glioblastoma;   Gliosarcoma;   Malignant Brain Tumor;   Neoplasm, Neuroepithelial;   Neuroectodermal Tumors;   Neoplasm by Histologic Type;   Neoplasm, Nerve Tissue;   Nervous System Diseases
Interventions: Biological: DNX-2401;   Biological: pembrolizumab
12 Recruiting Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy
Condition: Neuroendocrine Tumors
Intervention: Drug: AdVince
13 Not yet recruiting Adenovirus Vascular Endothelial Growth Factor D (AdvVEGF-D) Therapy for Treatment of Refractory Angina Pectoris
Conditions: Refractory Angina Pectoris;   Gene Transfer;   Coronary Artery Disease
Interventions: Drug: AdvVEGF-D;   Drug: Control Rx
14 Recruiting MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion in Patients With Incurable MAGE-A3-Expressing Solid Tumours
Condition: Advanced/Metastatic Solid Tumours
Interventions: Biological: MG1MA3;   Biological: AdMA3
15 Not yet recruiting Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients
Conditions: Malignant Hydrothorax;   Non Small Cell Lung Cancer
Interventions: Drug: Gemcitabine;   Drug: Vinorelbine;   Drug: Paclitaxel;   Drug: Pemetrexed;   Drug: Oncorine;   Drug: Endostar;   Drug: Cisplatin
16 Recruiting A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade
Condition: Advanced or Unresectable Melanoma Progressing After PD1 Blockade
Interventions: Biological: ONCOS-102;   Drug: Cyclophosphamide;   Drug: Pembrolizumab
17 Recruiting A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
Condition: To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy
Interventions: Biological: ONCOS-102;   Drug: Pemetrexed/cisplatin;   Drug: Cyclophosphamide
18 Recruiting Clinical Trial Phase I for Theragene in Combination With Chemotherapy for the Locally Advanced Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Biological: Theragene®,Ad5-yCD/mutTKSR39rep-ADP
19 Recruiting Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation
Conditions: CMV Infection;   EBV;   Adenovirus
Intervention: Biological: Virus specific CTLs
20 Recruiting Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)
Conditions: EBV;   CMV;   Adenovirus
Interventions: Drug: CTL for CMV seropositive donors;   Drug: CTL for CMV naïve donors

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.